NCT04683354: Phase I Study of HL-085 in Patients With Advanced Solid Tumor Tumors

NCT04683354
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients who have tested positive for COVID-19
https://ClinicalTrials.gov/show/NCT04683354

Comments are closed.

Up ↑